Nisha Pandey

Small-Cell Lung Cancer Is One Of The Hardest Cancers To Treat: What This New Drug Combination Could Change

Why Small-Cell Lung Cancer Is So Hard To Treat And What This New Drug Combination Could Change

Small-cell <span><a href="https://www.healthandme.com/health/lung-cancer">lung cancer</a></span> (<span>SCLC</span>) is one of the most aggressive forms of lung cancer. It tends to grow rapidly, spread early and often returns even after initially responding well to treatment.

A new drug combination from <span>Amgen</span> and <span>AstraZeneca</span> has shown a significant overall survival benefit in patients with extensive-stage small-cell lung cancer (ES-SCLC), offering a new way to delay the disease's return and progression.

On September 8, the companies said that the Phase III DeLLphi-305 trial found that combining Amgen's tarlatamab, marketed as Imdelltra, with AstraZeneca's durvalumab, marketed as Imfinzi, significantly improved overall survival compared with Imfinzi alone.

<h2>Small-Cell Lung Cancer Is Difficult To Treat</h2>

<a href="https://www.healthandme.com/health-wellness/fact-check-rahul-duas-cancer-claims-immunotherapy-isnt-always-better-superfoods-dont-cure-article-156102848" data-type="tilCustomLink">SCLC</a> accounts for a small percentage of lung cancers but it is particularly aggressive. The cancer cells can multiply quickly and spread to other organs, including the brain and liver.

The cancer can initially respond well to chemotherapy, but that response often does not last for a long time. 

Many tumours become resistant to treatment, allowing the disease to return and become harder to treat. Research has described recurrent SCLC as frequently resistant to further therapy.

This is particularly challenging disease goes in extensive stage, where the cancer has already spread beyond the lung. Even with current treatments, the median overall survival for <a href="https://www.healthandme.com/health-wellness/bbc-news-presenter-maryam-moshiri-reveals-incurable-blood-cancer-what-is-polycythemia-vera-article-156101058" data-type="tilCustomLink">ES-SCLC</a> remains around one year.

Also read: <a href="https://www.healthandme.com/health-news/25-years-after-9-11-what-new-records-reveal-about-toxic-air-in-new-york-article-156121508" data-type="tilCustomLink">25 Years After 9/11: What New Records Reveal About Toxic Air In New York</a>

<h2>How Does The New Drug Combination Work?</h2>

The two medicines attack the cancer through different mechanisms. Durvalumab is an immune checkpoint inhibitor. It blocks PD-L1, a <a href="https://www.healthandme.com/health-news/fda-approves-new-breast-cancer-treatment-that-targets-resistance-before-cancer-progresses-article-156100654" data-type="tilCustomLink">protein cancers</a> can use to evade the immune system, helping immune cells recognise and attack cancer cells.

Tarlatamab is a bispecific T-cell engager. It is designed to attach to DLL3 on small-cell lung cancer cells and CD3 on T cells, effectively bringing immune cells into contact with the cancer cells so they can destroy them. DLL3 is found on the surface of SCLC cells in about 85%-96% of patients but is minimally expressed on healthy cells.

In the trial, 563 patients whose disease had not progressed after initial treatment with Imfinzi plus platinum chemotherapy and etoposide were randomly assigned to receive either the combination or Imfinzi alone as maintenance treatment. 

The combination improved overall survival, progression-free survival and response rate. No new safety concerns were identified.

Also read: <a href="https://www.healthandme.com/health-wellness/exclusive-with-leading-hiv-expert-whats-driving-rising-hiv-cases-among-young-people-and-how-to-prevent-it-article-156121437" data-type="tilCustomLink">Exclusive With Leading HIV Expert: What's Driving Rising HIV Cases Among India's Youth And How To Prevent It</a>

Gas, Bloating & Acidity: Causes, Symptoms & When to See a Doctor

The significance of the findings lies in effectively controlling the <a href="https://www.healthandme.com/health-news/psychedelic-compound-found-in-magic-mushrooms-may-help-prevent-painful-chemotherapy-side-effects-study-finds-article-156097745" data-type="tilCustomLink">cancer</a> after initial treatment, when the disease is at the highest risk of returning.

Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, said: “Given the aggressive nature of <span>small cell <a href="https://www.healthandme.com/health/lung-cancer">lung cancer</a></span>, many patients quickly relapse on current therapy and never reach second-line treatment.” He added that the results suggest the potential to reshape the natural history of the disease.

Susan Galbraith, AstraZeneca's Executive Vice President of Oncology Haematology R&amp;D, said the results showed an “unprecedented improvement in overall survival” for patients with this highly aggressive cancer.

The full trial data are yet to be presented at a medical meeting and will be submitted to regulatory authorities.

Health Conditions A-Z

health

why-small-cell-lung-cancer-is-so-hard-to-treat-and-what-this-new-drug-combination-could-change

Small cell lung cancer

Amgen

AstraZeneca

sclc

small cell lung cancer treatment

lung cancer

25-years-after-9-11-what-new-records-reveal-about-toxic-air-in-new-york

25 Years After 9/11: What New Records Reveal About Toxic Air In New York

exclusive-with-leading-hiv-expert-whats-driving-rising-hiv-cases-among-young-people-and-how-to-prevent-it

Exclusive With Leading HIV Expert: What's Driving Rising HIV Cases Among India's Youth And How To Prevent It

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Small-cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer. It tends to grow rapidly, spread early and often returns even after initially responding well to treatment.A new drug combination from Amgen and AstraZeneca has shown a significant overall survival benefit in patients with extensive-stage small-cell lung cancer (ES-SCLC), offering a new way to delay the disease's return and progression.On September 8, the companies said that the Phase III DeLLphi-305 trial found that combining Amgen's tarlatamab, marketed as Imdelltra, with AstraZeneca's durvalumab, marketed as Imfinzi, significantly improved overall survival compared with Imfinzi alone.Small-Cell Lung Cancer Is Difficult To TreatSCLC accounts for a small percentage of lung cancers but it is particularly aggressive. The cancer cells can multiply quickly and spread to other organs, including the brain and liver.The cancer can initially respond well to chemotherapy, but that response often does not last for a long time. Many tumours become resistant to treatment, allowing the disease to return and become harder to treat. Research has described recurrent SCLC as frequently resistant to further therapy.This is particularly challenging disease goes in extensive stage, where the cancer has already spread beyond the lung. Even with current treatments, the median overall survival for ES-SCLC remains around one year.Also read: 25 Years After 9/11: What New Records Reveal About Toxic Air In New YorkHow Does The New Drug Combination Work?The two medicines attack the cancer through different mechanisms. Durvalumab is an immune checkpoint inhibitor. It blocks PD-L1, a protein cancers can use to evade the immune system, helping immune cells recognise and attack cancer cells.Tarlatamab is a bispecific T-cell engager. It is designed to attach to DLL3 on small-cell lung cancer cells and CD3 on T cells, effectively bringing immune cells into contact with the cancer cells so they can destroy them. DLL3 is found on the surface of SCLC cells in about 85%-96% of patients but is minimally expressed on healthy cells.In the trial, 563 patients whose disease had not progressed after initial treatment with Imfinzi plus platinum chemotherapy and etoposide were randomly assigned to receive either the combination or Imfinzi alone as maintenance treatment. The combination improved overall survival, progression-free survival and response rate. No new safety concerns were identified.Also read: Exclusive With Leading HIV Expert: What's Driving Rising HIV Cases Among India's Youth And How To Prevent ItHope For Patients With SCLC   The significance of the findings lies in effectively controlling the cancer after initial treatment, when the disease is at the highest risk of returning.Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, said: “Given the aggressive nature of small cell lung cancer, many patients quickly relapse on current therapy and never reach second-line treatment.” He added that the results suggest the potential to reshape the natural history of the disease.Susan Galbraith, AstraZeneca's Executive Vice President of Oncology Haematology R&D, said the results showed an “unprecedented improvement in overall survival” for patients with this highly aggressive cancer.The full trial data are yet to be presented at a medical meeting and will be submitted to regulatory authorities.

small-cell lung cancer is one of the hardest cancers to treat: what this new drug combination could change

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Small-Cell Lung Cancer Is One Of The Hardest Cancers To Treat: What This New Drug Combination Could Change

25 Years After 9/11: What New Records Reveal About Toxic Air In New York

Leptospirosis Cases Surge In Manila After Floods: What To Know

Weight Loss Surgery May Improve Irregular Periods And Other PMOS Symptoms

Health Conditions A-Z

Small-Cell Lung Cancer Is One Of The Hardest Cancers To Treat: What This New Drug Combination Could Change

25 Years After 9/11: What New Records Reveal About Toxic Air In New York

Exclusive With Leading HIV Expert: What's Driving Rising HIV Cases Among India's Youth And How To Prevent It